Sign in

Thomas Trimarchi

Research Analyst at Raymond James

Thomas Trimarchi is President and Chief Financial Officer at BridgeBio Pharma, specializing in the discovery and commercialization of genetic disease therapies, and also serves as a Director at ML Bio Solutions. He has played a key leadership role in advancing BridgeBio’s pipeline and operations since joining in 2018, with previous experience at Regeneron Pharmaceuticals and Goldman Sachs. Trimarchi’s oversight includes financial management and strategic operations, directly contributing to substantial revenue growth; he has executed significant equity transactions and facilitated company performance recognized by multiple analyst firms, including Raymond James. He holds a Ph.D. in Molecular Oncology and Immunology from New York University and has steadily progressed through senior executive roles in biopharma, though there are no indications of securities analyst credentials or FINRA licenses.

Thomas Trimarchi's questions to BridgeBio Pharma (BBIO) leadership

Question · Q3 2025

Thomas Trimarchi, on behalf of Martin Oster, asked for more details on the serious treatment-related adverse events (TEAEs) observed with Encalirate in periods two and three of its trial, and on standard of care in period one.

Answer

Neil Kumar, CEO and Founder, BridgeBio Pharma, clarified that the serious TEAEs were related to hypercalcemia. He noted that hypercalcemia on standard of care was quite high, requiring hospitalization, while Encalirate-related hypercalcemia was much milder, with the patient hospitalized for unrelated issues (altered mental status and UTI) and subsequently dosed down without discontinuation. Kumar emphasized that Encalirate led to fewer discontinuations than standard of care, highlighting its safety due to its precise allosteric mechanism.

Ask follow-up questions

Fintool

Fintool can predict BridgeBio Pharma logo BBIO's earnings beat/miss a week before the call

Let Fintool AI Agent track Thomas Trimarchi for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free